Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes
Diabetes Mellitus, Type 2

About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2
Eligibility Criteria
Inclusion criteria:
- Signed and dated ICF (Informed Consent Form)
- Male or female on diet and exercise regime and on stable background metformin > or equal to 1500 mg or maximun dose according to local label
- HBA1c (Glicoslated Hemoglobin) > or equal to 8% and < or equal to 10.5 % at Visit 1
- HbA1c > or equal to 7 and < or equal to 10.5 at Visit 4
- Age > or equal to 18 years
- BMI (Body Mass Index) < or equal to 45
Exclusion criteria:
- Uncontrolled hyperglycemia during open label period and placebo add on "run-in" period
- Use of any other antidiabetic
- Renal function below 60 ml/min/1.73 m2
- Antiobesity drugs or aggresive diets
- Gastorintestinal surgeries
- Current systemic steroids or uncontrolled endocrine disorders other than Diabetes Type 2
- Acute coronary syndrome and stroke within 3 months of informed consent
- Known allergies to DPP-IV (Dypeptidil Peptidase IV) or SGLT-2 (Sodium Glucose Transporter 2) inhibitors
Sites / Locations
- 1275.10.01019 Boehringer Ingelheim Investigational Site
- 1275.10.01008 Boehringer Ingelheim Investigational Site
- 1275.10.01003 Boehringer Ingelheim Investigational Site
- 1275.10.01024 Boehringer Ingelheim Investigational Site
- 1275.10.01002 Boehringer Ingelheim Investigational Site
- 1275.10.01011 Boehringer Ingelheim Investigational Site
- 1275.10.01009 Boehringer Ingelheim Investigational Site
- 1275.10.01023 Boehringer Ingelheim Investigational Site
- 1275.10.01006 Boehringer Ingelheim Investigational Site
- 1275.10.01017 Boehringer Ingelheim Investigational Site
- 1275.10.01016 Boehringer Ingelheim Investigational Site
- 1275.10.01012 Boehringer Ingelheim Investigational Site
- 1275.10.01013 Boehringer Ingelheim Investigational Site
- 1275.10.01010 Boehringer Ingelheim Investigational Site
- 1275.10.01001 Boehringer Ingelheim Investigational Site
- 1275.10.01007 Boehringer Ingelheim Investigational Site
- 1275.10.01005 Boehringer Ingelheim Investigational Site
- 1275.10.01020 Boehringer Ingelheim Investigational Site
- 1275.10.01022 Boehringer Ingelheim Investigational Site
- 1275.10.01021 Boehringer Ingelheim Investigational Site
- 1275.10.01014 Boehringer Ingelheim Investigational Site
- 1275.10.01018 Boehringer Ingelheim Investigational Site
- 1275.10.01015 Boehringer Ingelheim Investigational Site
- 1275.10.01025 Boehringer Ingelheim Investigational Site
- 1275.10.54005 Boehringer Ingelheim Investigational Site
- 1275.10.54012 Boehringer Ingelheim Investigational Site
- 1275.10.54002 Boehringer Ingelheim Investigational Site
- 1275.10.54007 Boehringer Ingelheim Investigational Site
- 1275.10.54013 Boehringer Ingelheim Investigational Site
- 1275.10.54006 Boehringer Ingelheim Investigational Site
- 1275.10.54008 Boehringer Ingelheim Investigational Site
- 1275.10.54011 Boehringer Ingelheim Investigational Site
- 1275.10.54003 Boehringer Ingelheim Investigational Site
- 1275.10.54009 Boehringer Ingelheim Investigational Site
- 1275.10.54004 Boehringer Ingelheim Investigational Site
- 1275.10.54001 Boehringer Ingelheim Investigational Site
- 1275.10.54010 Boehringer Ingelheim Investigational Site
- 1275.10.61008 Boehringer Ingelheim Investigational Site
- 1275.10.61002 Boehringer Ingelheim Investigational Site
- 1275.10.61001 Boehringer Ingelheim Investigational Site
- 1275.10.61009 Boehringer Ingelheim Investigational Site
- 1275.10.02004 Boehringer Ingelheim Investigational Site
- 1275.10.02001 Boehringer Ingelheim Investigational Site
- 1275.10.02003 Boehringer Ingelheim Investigational Site
- 1275.10.02009 Boehringer Ingelheim Investigational Site
- 1275.10.02012 Boehringer Ingelheim Investigational Site
- 1275.10.02006 Boehringer Ingelheim Investigational Site
- 1275.10.02008 Boehringer Ingelheim Investigational Site
- 1275.10.02005 Boehringer Ingelheim Investigational Site
- 1275.10.02013 Boehringer Ingelheim Investigational Site
- 1275.10.02002 Boehringer Ingelheim Investigational Site
- 1275.10.02007 Boehringer Ingelheim Investigational Site
- 1275.10.02011 Boehringer Ingelheim Investigational Site
- 1275.10.02010 Boehringer Ingelheim Investigational Site
- 1275.10.34014 Boehringer Ingelheim Investigational Site
- 1275.10.49007 Boehringer Ingelheim Investigational Site
- 1275.10.49014 Boehringer Ingelheim Investigational Site
- 1275.10.49016 Boehringer Ingelheim Investigational Site
- 1275.10.49012 Boehringer Ingelheim Investigational Site
- 1275.10.49005 Boehringer Ingelheim Investigational Site
- 1275.10.49008 Boehringer Ingelheim Investigational Site
- 1275.10.49004 Boehringer Ingelheim Investigational Site
- 1275.10.49010 Boehringer Ingelheim Investigational Site
- 1275.10.49003 Boehringer Ingelheim Investigational Site
- 1275.10.49006 Boehringer Ingelheim Investigational Site
- 1275.10.49013 Boehringer Ingelheim Investigational Site
- 1275.10.49001 Boehringer Ingelheim Investigational Site
- 1275.10.49015 Boehringer Ingelheim Investigational Site
- 1275.10.39005 Boehringer Ingelheim Investigational Site
- 1275.10.39006 Boehringer Ingelheim Investigational Site
- 1275.10.39009 Boehringer Ingelheim Investigational Site
- 1275.10.39014 Boehringer Ingelheim Investigational Site
- 1275.10.39007 Boehringer Ingelheim Investigational Site
- 1275.10.39012 Boehringer Ingelheim Investigational Site
- 1275.10.39013 Boehringer Ingelheim Investigational Site
- 1275.10.39015 Boehringer Ingelheim Investigational Site
- 1275.10.39016 Boehringer Ingelheim Investigational Site
- 1275.10.39004 Boehringer Ingelheim Investigational Site
- 1275.10.39003 Boehringer Ingelheim Investigational Site
- 1275.10.39008 Boehringer Ingelheim Investigational Site
- 1275.10.39001 Boehringer Ingelheim Investigational Site
- 1275.10.39010 Boehringer Ingelheim Investigational Site
- 1275.10.39011 Boehringer Ingelheim Investigational Site
- 1275.10.35104 Boehringer Ingelheim Investigational Site
- 1275.10.35112 Boehringer Ingelheim Investigational Site
- 1275.10.35103 Boehringer Ingelheim Investigational Site
- 1275.10.35105 Boehringer Ingelheim Investigational Site
- 1275.10.35108 Boehringer Ingelheim Investigational Site
- 1275.10.35101 Boehringer Ingelheim Investigational Site
- 1275.10.07004 Boehringer Ingelheim Investigational Site
- 1275.10.07006 Boehringer Ingelheim Investigational Site
- 1275.10.07001 Boehringer Ingelheim Investigational Site
- 1275.10.07005 Boehringer Ingelheim Investigational Site
- 1275.10.07003 Boehringer Ingelheim Investigational Site
- 1275.10.07002 Boehringer Ingelheim Investigational Site
- 1275.10.34003 Boehringer Ingelheim Investigational Site
- 1275.10.34004 Boehringer Ingelheim Investigational Site
- 1275.10.34008 Boehringer Ingelheim Investigational Site
- 1275.10.34009 Boehringer Ingelheim Investigational Site
- 1275.10.34012 Boehringer Ingelheim Investigational Site
- 1275.10.34006 Boehringer Ingelheim Investigational Site
- 1275.10.34010 Boehringer Ingelheim Investigational Site
- 1275.10.34011 Boehringer Ingelheim Investigational Site
- 1275.10.34001 Boehringer Ingelheim Investigational Site
- 1275.10.34013 Boehringer Ingelheim Investigational Site
- 1275.10.34002 Boehringer Ingelheim Investigational Site
- 1275.10.34005 Boehringer Ingelheim Investigational Site
- 1275.10.38006 Boehringer Ingelheim Investigational Site
- 1275.10.38007 Boehringer Ingelheim Investigational Site
- 1275.10.38002 Boehringer Ingelheim Investigational Site
- 1275.10.38003 Boehringer Ingelheim Investigational Site
- 1275.10.38004 Boehringer Ingelheim Investigational Site
- 1275.10.38001 Boehringer Ingelheim Investigational Site
- 1275.10.38005 Boehringer Ingelheim Investigational Site
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm 7
Arm 8
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Empagliflozin 10 mg dose
Placebo add on 10 mg dose
Empagliflozin/Linagliptin 25/5 mg Dose
Empagliflozin/Linagliptin 10/5 mg Dose.
Empagliflozin/Linagliptin 10/5 mg Dose
Empagliflozin 25 mg dose
Empagliflozin/Linagliptin 25/5 mg Dose.
Placebo add on 25 mg dose
Empagliflozin open label treatment period
Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo add on run-in
Empagliflozin / Linagliptin 25/5 mg Dose FDC active
Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo
Empagliflozin / Linagliptin 10/5 mg Dose FDC active
Empagliflozin open label treatment period
Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo add on run-in